Bronchiectasis Therapeutic Market Analysis

Product Type (Antibiotics, Expectorants)

Based on type, the antibiotic segment in the bronchiectasis therapeutic market is set to hold the highest CAGR of 70% during the forecast period 2024-2036. The growth of this market can be primarily attributed to the back of increasing prevalence of respiratory disorders. As healthcare providers become more aware of the risks of antibiotic overuse, there is a growing demand for targeted antibiotic therapy that is specific to the bacteria causing the infection. Pharmaceutical companies are developing new antibiotics that are specifically designed to treat bacterial infections in patients with bronchiectasis.

Distribution Channel (Hospital, Online, Retail Pharmacies)

In terms of distribution channels, the online pharmacy segment in the bronchiectasis therapeutic market is set to hold the highest CAGR of 50% during the forecast period. Online pharmacies offer patients the convenience of ordering their medication from home and having it delivered directly to their door. This can be especially helpful for patients with bronchiectasis who may have difficulty traveling to a physical pharmacy owing to their symptoms. Online pharmacies can often offer lower prices on medications than traditional brick-and-mortar pharmacies. This is because they have lower overhead costs and can negotiate better deals with drug manufacturers. This segment rapidly grew during the COVID-19 pandemic period as well. CVS Health reported a rise of 1000% in online sales of prescription drugs in covid time.

Our in-depth analysis of the global bronchiectasis therapeutic market includes the following segments: